Impact of sFlt-1/PlGF ratio availability on intended management decisions in hypertensive disorders of pregnancy with diagnostic uncertainty: experience from a medical education event.

Hypertensive disorders of pregnancy affect 13-16% of U.S. pregnancies and remain a leading cause of maternal and neonatal morbidity. Management is complicated by diagnostic uncertainty, as most markers rise only after end-organ injury. The sFlt-1/PlGF ratio has shown strong prognostic value, but its effect, on U.S. clinical management decisions, is unknown. We conducted a case-based webinar with obstetric and maternal-fetal medicine providers (n = 68) to assess changes in management intent after a low ratio result. Expectant management intent rose from 20.9% to 87.8%, while delivery intent decreased. These findings suggest sFlt-1/PlGF biomarker data may influence intended patient management.